Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Pharm Sci. 2020 Sep 12;109(12):3716–3727. doi: 10.1016/j.xphs.2020.09.011

Figure 9.

Figure 9.

SUDV-GP accelerated stability study results for size-exclusion chromatography and vaccine immunogenicity. (a) Area under the entire chromatogram was calculated and normalized to areas of each unincubated formulation to represent protein retention over time, shown in red markers on the right y-axis. Error bars are standard deviation from the average of three replicates. Total soluble protein area was divided into HMW, monomer, and monomer folding variants and is shown as the percent of the total area as bars on the left y-axis. (b) Mouse immunogenicity of SUDV-GP lyophilized formulations with varying salt levels compared to liquid in PBS formulations shown as GMTs +/− 95% confidence interval. Each dot represents the antibody concentration from serum of one individual mouse. The dotted line represents the LOQ, with values below this limit shown as half the LOQ.